Existing liquid biopsy technologies have impacted millions of patients with cancer over the last decade and the precision medicine application space for Precede transcends that of even the most successful of these liquid biopsy technologies creating a significant opportunity for us to impact the practice of medicine. Precede has yet to publish papers to support its claims but will share scientific data later this month